Q-omics provides the consensus-scored PCDHB5 profile across patient tissues and cancer cell-line models. PCDHB5 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, PCDHB5 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, PCDHB5 protein abundance shows 15,556 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight STAD, KICH, and LSCC as cancer lineages where PCDHB5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCDHB5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCDHB5 survival associations across molecular data types. PCDHB5 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (11) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCDHB5 RNA expression–survival associations across cancer types. High PCDHB5 expression shows unfavorable associations in STAD and BLCA, but favorable associations in PAAD, MESO, ESCA and OV. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify STAD as the clearest survival context for PCDHB5 RNA expression.
This table summarizes PCDHB5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KICH for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PCDHB5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCDHB5 shows lower tumor expression in KICH, UCEC, KIRC, THCA, BRCA and COAD. The KICH box plot shows higher PCDHB5 RNA expression in normal versus tumor tissue (log2 FC = −3.433, t-test p < 0.001).
This table shows molecular features associated with PCDHB5 in patient tissues and cancer cell lines. In patient samples, PCDHB5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PCDHB5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
